1. 1. Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, Chen DC and Hai-Bin X. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med 5(9): 743-748, 2012
2. 2. Russell RG and Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106, 1999
3. 3. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB and Rodan GA. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA 93(7): 3068-3073, 1996
4. 4. Otero JE, Stevens JW, Malandra AE, Fredericks DC, Odgren PR, Buckwalter JA and Morcuende J. Osteoclast inhibition impairs chondrosarcoma growth and bone destruction. J Orthop Res 32(12): 1562-1571, 2014
5. 5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9): 1115-1117, 2003